Macugen for Histoplasmosis

Inclusion Criteria: * Diagnosis of ocular histoplasmosis, * Evidence of classic or occult choroidal neovascularization extending under the geometric center of the fovea, * Greatest linear diameter of no greater than 5400 microns, * Best-corrected visual acuity scores between 20/40-20/200, * Ability to give informed consent, * Limited child bearing potential and a negative pregnancy test Exclusion Criteria: * Features of any condition other than OHS such as AMD, or pathologic or myopic angioid streaks associated with CNV in the study eye, * Area of CNV that is less than 50% of the total lesion not including area of prior laser treatment, previous rip of retinal pigment epithelium, * Vitelliform-like lesion, * Telangiectasia, * Central serous retinopathy, * Serous pigment epithelial detachment without CNV, * Any significant ocular disease other than CNV that could compromise vision in the study eye, such as amblyopia, glaucoma, optic neuropathy, or diabetic retinopathy, * Inability to obtain photographs to document CNV, * Presence of atrophy/scar in the center of fovea, * Presence of vitreo-retinal traction over the center of the fovea, * History of treatment for CNV in the study eye other than non-foveal laser photocoagulation,within 12 weeks prior to enrollment * Participation in another clinical trial or use of another investigational new drug within 12 weeks of the full extent of the study treatment, * Intraocular surgery within the last two months, * Capsulectomy within…